Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial

David I. Marks, Amy A. Kirkwood, Clare J. Rowntree, Melanie Aguiar, Katharine E. Bailey, Brendan Beaton, Paul Cahalin, Anna Z. Castleton, Laura Clifton-Hadley, Mhairi Copland, Anthony H. Goldstone, Richard Kelly, Emma Lawrie, Soo Wah Lee, Andrew K. McMillan, Mary Frances McMullin, Tobias F. Menne, Rachel J. Mitchell, Anthony V. Moorman, Bela PatelPip Patrick, Paul Smith, David Taussig, Deborah Yallop, Krisztina Zuborne Alapi, Adele K. Fielding

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences